Nat Med. 2010 Dec;16(12):1351. doi: 10.1038/nm1210-1351.
In July, the global health financing mechanism UNITAID established an intellectual property-sharing scheme focused on scaling up access to new and lower-priced antiretroviral drugs in the developing world. The initiative-called the Medicines Patent Pool (MPP)-aims to streamline licensing processes, drive the combination of multiple HIV medicines into one pill and foster the development of drug formulations for children. In September, the US National Institutes of Health (NIH) became the first contributor to the venture, licensing a suite of patents related to protease inhibitors that are used to treat HIV. The task of bringing drug firms and other key stakeholders into the fold now falls on Ellen 't Hoen, a lawyer who became MPP's executive director last month after previously heading up Médecins Sans Frontières' Campaign for Access to Essential Medicines. Asher Mullard spoke to Hoen about the challenges of encouraging companies to share their intellectual property in a normally guarded sector.
7 月，全球卫生筹资机制 UNITAID 建立了一个知识产权共享机制，专注于扩大发展中国家获得新的、价格更低的抗逆转录病毒药物的机会。该倡议被称为“医药专利池”（MPP），旨在简化许可程序，推动将多种 HIV 药物组合成一种药丸，并促进儿童用药制剂的开发。9 月，美国国立卫生研究院（NIH）成为该项目的第一个贡献者，授权了一套与蛋白酶抑制剂相关的专利，这些专利用于治疗 HIV。现在，将制药公司和其他关键利益相关者纳入该计划的任务落在了 Ellen 't Hoen 身上。她是一名律师，上个月成为 MPP 的执行董事，此前她曾领导无国界医生组织的获取基本药物运动。Asher Mullard 与 Hoen 就鼓励公司在一个通常受到严密保护的领域共享知识产权的挑战进行了交谈。
